CVC, Temasek 'exploring options' for Alvogen
Hong Kong
ALVOGEN'S owners - including CVC Capital Partners and Temasek Holdings - are said to be exploring options for the generic pharmaceutical company, which could be valued at about US$4 billion, according to people familiar with the matter.
The controlling shareholders of the drugmaker have held on-and-off talks with Shanghai Pharmaceuticals Holding Co focusing on a sale of Alvogen's US business, the people said. Alvogen would keep its operations in Asia as well as central and eastern Europe, one of the people said.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Beijing city to subsidise domestic AI chips, targets self-reliance by 2027
Hong Kong bourse regains favour on hopes of a market revival
Chinese sellers go to TikTok school to reach buyers abroad
Gold prices set for weekly decline ahead of US inflation data
Huawei’s new phone sports latest version of made-in-China chip
Meta’s earnings flop sparks US$400 billion sell-off in tech stocks